Oscar Health (OSCR) Stock Overview
Operates as a healthcare technology company in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
OSCR Community Fair Values
Create NarrativeSee what 153 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
US$45.34
FV
31.1% undervalued intrinsic discount122
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
14users have followed this narrative
Oscar Health, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$31.23 |
| 52 Week High | US$33.10 |
| 52 Week Low | US$10.69 |
| Beta | 2.34 |
| 1 Month Change | 9.50% |
| 3 Month Change | 68.90% |
| 1 Year Change | 122.28% |
| 3 Year Change | 338.62% |
| 5 Year Change | 100.19% |
| Change since IPO | -10.26% |
Recent News & Updates
Narrative Update • Jul 25
OSCR: ACA Exchange Risk Adjustment Tailwind Will Not Offset Margin Concerns
Analysts have lifted the implied fair value estimate for Oscar Health from $22.60 to $24.20, citing more supportive views on the 2025 healthcare exchange risk adjustment true up and the company’s focused exposure to the individual ACA market, even as margin expectations remain measured and the future P/E assumption edges up toward 11x. Analyst Commentary Recent research on Oscar Health centers on how the individual Affordable Care Act market, risk adjustment outcomes, and margin trajectory could feed into valuation over the next few years.Seeking Alpha • Jul 22
Oscar Health: Strong Numbers Forced Re-Rating, Now Pay Attention To Continuous Execution
Summary Oscar Health has rerated to the $30 range, reflecting its strong performance but reduced asymmetry versus prior opportunities. Risk Adjustment Transfer dynamics and plan mix will pressure EPS and margins in Q2 and beyond, despite an encouraging Q1 medical loss ratio. I expect MLR to rise to the mid-to-high seventies and negative EPS for upcoming quarters, with SG&A likely flat as tech efficiencies are offset. I assign OSCR a Buy rating with a $37 target, reflecting a 15x P/E on probability-weighted $2.45 EPS, but urge a more cautious, execution-focused approach. Read the full article on Seeking Alpha
Narrative Update • Jul 10
OSCR: ACA Risk Adjustment Tailwinds Will Confront Ongoing Margin Execution Concerns
Analysts have lifted their fair value estimate for Oscar Health from $11.00 to $13.00 per share, citing more favorable healthcare exchange risk adjustment dynamics, expectations for margin recovery as repricing actions flow through, and increased comfort with the individual ACA market exposure, as reflected in higher Street price targets from firms such as Barclays and Wells Fargo. Analyst Commentary on Oscar Health Recent Street commentary on Oscar Health has centered on how the company is positioned within the individual Affordable Care Act market and how current healthcare exchange risk adjustment mechanics could influence results.Recent updates
Narrative Update • Jul 25
OSCR: ACA Exchange Risk Adjustment Tailwind Will Not Offset Margin Concerns
Analysts have lifted the implied fair value estimate for Oscar Health from $22.60 to $24.20, citing more supportive views on the 2025 healthcare exchange risk adjustment true up and the company’s focused exposure to the individual ACA market, even as margin expectations remain measured and the future P/E assumption edges up toward 11x. Analyst Commentary Recent research on Oscar Health centers on how the individual Affordable Care Act market, risk adjustment outcomes, and margin trajectory could feed into valuation over the next few years.Seeking Alpha • Jul 22
Oscar Health: Strong Numbers Forced Re-Rating, Now Pay Attention To Continuous Execution
Summary Oscar Health has rerated to the $30 range, reflecting its strong performance but reduced asymmetry versus prior opportunities. Risk Adjustment Transfer dynamics and plan mix will pressure EPS and margins in Q2 and beyond, despite an encouraging Q1 medical loss ratio. I expect MLR to rise to the mid-to-high seventies and negative EPS for upcoming quarters, with SG&A likely flat as tech efficiencies are offset. I assign OSCR a Buy rating with a $37 target, reflecting a 15x P/E on probability-weighted $2.45 EPS, but urge a more cautious, execution-focused approach. Read the full article on Seeking AlphaNarrative Update • Jul 10
OSCR: ACA Risk Adjustment Tailwinds Will Confront Ongoing Margin Execution Concerns
Analysts have lifted their fair value estimate for Oscar Health from $11.00 to $13.00 per share, citing more favorable healthcare exchange risk adjustment dynamics, expectations for margin recovery as repricing actions flow through, and increased comfort with the individual ACA market exposure, as reflected in higher Street price targets from firms such as Barclays and Wells Fargo. Analyst Commentary on Oscar Health Recent Street commentary on Oscar Health has centered on how the company is positioned within the individual Affordable Care Act market and how current healthcare exchange risk adjustment mechanics could influence results.
Narrative Update • Jun 26
OSCR: ACA Market Momentum Will Shape Margin Recovery Through 2026
The updated analyst price target for Oscar Health has shifted from $23.00 to $34.47. This reflects analysts' view that the company's focused exposure to the individual ACA market and expectations for margin recovery justify using a higher future P/E multiple and slightly stronger profit margin assumptions, despite somewhat lower projected revenue growth.Narrative Update • Jun 12
OSCR: ACA Exchange Reliance Will Test Margin Durability Beyond 2026
Analysts have lifted their fair value estimate for Oscar Health from $15.40 to $22.60, citing higher confidence in margin improvement and the company's focused exposure to the individual ACA market. This has supported a series of price target increases and rating upgrades across the Street.Narrative Update • May 29
OSCR: Higher Managed Care Optimism Will Clash With Slower Revenue Assumptions
Oscar Health’s updated analyst price target of $30, up from $21, reflects analysts’ view that the recent managed care stock moves after Q1 results are durable, with a relative preference for managed care over facilities given perceived earnings risks for providers tied to inflation and commercial mix. Analyst Commentary Recent research on Oscar Health points to a more balanced stance, with some analysts highlighting upside potential while others flag risks around valuation, execution, and the durability of managed care trends following the latest Q1 updates.Narrative Update • May 02
OSCR: Regulatory Probe And Exchange Pressures Will Constrain Future Profitability
Analysts have adjusted the Oscar Health price target from $10 to $11, citing updated assumptions around revenue growth, profit margins, and future P/E that reflect recent research views from multiple firms. Analyst Commentary Street research around Oscar Health reflects mixed views, with some analysts revisiting models on revenue growth, profitability, and valuation multiples.Narrative Update • Apr 16
OSCR: Subsidy And Regulatory Pressures Will Restrain Exchange Profitability
Analysts have adjusted Oscar Health's price target to $10, reflecting updated views on revenue growth, profit margins, and a lower assumed future P/E multiple following recent rating and target changes from the Street. Analyst Commentary Recent Street research on Oscar Health reflects a mix of optimism and caution, with some firms updating ratings while others adjust price targets and factor in sector developments.Narrative Update • Apr 01
OSCR: Enrollment Resilience And 2026 Profit Outlook Will Drive Future Earnings Power
Narrative Update on Oscar Health The analyst price target for Oscar Health has shifted modestly, with the revised fair value moving from about $15.78 to $15.40 as analysts factor in updated views on revenue growth, profit margins, and a lower forward P/E multiple alongside recent rating changes and price target adjustments. Analyst Commentary Recent Street research around Oscar Health reflects a mix of optimism and caution, with price target resets and rating changes feeding into the modestly reduced fair value estimate.Narrative Update • Mar 18
OSCR: Exchange Enrollment Resilience And Subpoena Overhang Will Shape 2026 Outlook
Narrative Update on Oscar Health Analysts have trimmed Oscar Health's average price target by $2, citing updated views on exchange enrollment trends, the impact of recent rebate developments at a major competitor, and a modest reset of revenue growth, profit margin, and future P/E assumptions. Analyst Commentary Recent Street research on Oscar Health reflects a mix of caution on short term assumptions and growing confidence in the company’s ability to execute on its exchange strategy.Narrative Update • Mar 04
OSCR: Exchange Enrollment Resilience And 2026 Outlook Will Drive Future Upside
Narrative Update on Oscar Health Analysts have adjusted their average price target on Oscar Health to $23.00 from $24.15. This reflects updated views on revenue growth, profit margin potential, and a lower assumed future P/E multiple following recent ratings changes and commentary from major research firms.Narrative Update • Feb 18
OSCR: Subsidy Expiration Risk Will Pressure Exchange Enrollment And Profitability
Oscar Health's analyst price targets have been recalibrated, and our fair value estimate has moved from $8.00 to $10.00 as analysts factor in updated views on revenue growth, profitability and future P/E assumptions following several recent rating upgrades and target changes. Analyst Commentary Recent Street research on Oscar Health reflects a mix of optimism and caution as analysts update their models for revenue, profitability and P/E assumptions.Analysis Article • Feb 13
Oscar Health, Inc. (NYSE:OSCR) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
It's shaping up to be a tough period for Oscar Health, Inc. ( NYSE:OSCR ), which a week ago released some disappointing...Analysis Article • Feb 12
New Forecasts: Here's What Analysts Think The Future Holds For Oscar Health, Inc. (NYSE:OSCR)
Oscar Health, Inc. ( NYSE:OSCR ) shareholders will have a reason to smile today, with the analysts making substantial...Narrative Update • Feb 03
OSCR: Pricing Discipline And Florida Expansion Will Shape Future Earnings Power
Analysts have nudged their fair value estimate for Oscar Health higher to about $15.78 from $15.22, citing updated work on pricing and benefit design, exchange enrollment resilience despite subsidy changes, and expectations for a slightly richer future P/E multiple. Analyst Commentary Recent Street research on Oscar Health points to a mix of optimism about execution in key markets and some lingering caution around pricing, product mix, and longer term earnings power.Narrative Update • Jan 20
OSCR: Miami Dade Execution And Exchange Resilience Will Drive Future Upside
Analysts have raised their price target on Oscar Health to about $24.15 from $14.00, citing improved views on the company’s ability to grow exchange enrollment and earnings power. Some also highlight what they see as fairly valued shares and the potential for both market share gains and profitability in key regions like Miami-Dade.Narrative Update • Jan 06
OSCR: Premium Hikes And New Market Expansion Will Shape Future Margins
Oscar Health's analyst fair value estimate in our framework has shifted from about $14.67 to $15.22. This reflects analysts' higher price targets and upgraded ratings following recent research that highlights potential for share gains and profitability improvements in key markets.Narrative Update • Dec 19
OSCR: Premium Hikes And AI Product Expansion Will Shape Future Margin Outcomes
Oscar Health's fair value estimate has inched up to approximately $14.67 per share from about $14.38 as analysts factor in higher long term earnings power, supported by recent price target upgrades into the mid teens and low $20s that cite improved benefit design, pricing strategy, and the potential for sustained profitability even under conservative policy assumptions. Analyst Commentary Recent Street research presents a mixed but generally improving picture for Oscar Health, with multiple firms revising price targets upward while maintaining differing views on risk, execution, and the durability of growth.Narrative Update • Dec 04
OSCR: Aggressive Premium Hikes Will Test Margin Recovery Amid Policy Uncertainty
The analyst price target for Oscar Health has been raised meaningfully, with fair value increasing from $12.88 to $14.38 per share. Analysts attribute this change to stronger long-term revenue growth prospects, slightly lower perceived risk, and higher future earnings multiples, despite modestly lower margin assumptions.Narrative Update • Nov 20
OSCR: Premium Rate Increases And Margin Recovery Will Shape Path To 2026
Oscar Health's analyst fair value price target increased by $0.50 to $12.88. Analysts cite improved premium rates and stronger product competitiveness following recent updates.Analysis Article • Nov 07
Positive Sentiment Still Eludes Oscar Health, Inc. (NYSE:OSCR) Following 26% Share Price Slump
The Oscar Health, Inc. ( NYSE:OSCR ) share price has softened a substantial 26% over the previous 30 days, handing back...Narrative Update • Nov 06
OSCR: Margin Recovery Challenges Expected to Weigh on Path to 2026 Profitability
Oscar Health's analyst price targets have recently shifted modestly upward, with the average target rising to around $13 to $14 per share as analysts cite updated industry outlooks, expected subsidy extensions, and company guidance for a potential return to profitability in 2026. Analyst Commentary Recent analyst coverage of Oscar Health reflects a mix of cautious optimism along with some lingering concerns about the company's near-term execution and long-term recovery prospects.Narrative Update • Oct 23
Analysts Raise Oscar Health Price Target amid Profitability Hopes and New Healthcare Initiatives
Oscar Health's analyst price target has increased from $11.71 to $12.38 per share, as analysts point to sector outlook updates and a gradual improvement in projected profitability margins. Analyst Commentary Recent analyst research on Oscar Health highlights a mix of optimism and caution regarding the company's valuation, future profitability, and sector trends.Narrative Update • Oct 08
ACA Uncertainties And Digital Efficiencies Will Shape Future Outcomes
Oscar Health's analyst price target has risen modestly from $11.14 to $11.71 per share. This change reflects analysts' expectations for improved revenue growth and profit margins, despite ongoing uncertainty in the health insurance marketplace.Seeking Alpha • Mar 09
Oscar Health: The Most Undervalued Small Cap But With One Big Risk
Summary I am bullish on Oscar Health (OSCR) due to its efficient D2C model, AI integration, and improving EBITDA margins despite high revenue growth. OSCR's opportunity in the ICHRA market is significant, with projections to increase 3x-5x by 2030, positioning it well against larger competitors. Risks include potential changes to ACA subsidies under future administrations, which could disrupt OSCR's current business model and force a shift to ICHRA. OSCR trades at a low valuation despite 67% revenue growth, suggesting a potential 10x upside if market risks are mitigated. Read the full article on Seeking AlphaSeeking Alpha • Feb 13
Oscar Health: Looking Like A Cheap High-Growth Company, But Not Without A Catch
Summary Oscar Health's heavy reliance on ACA is dangerous. Expiration of extended ACA subsidies in 2025 could severely impact the company. I plan to short Oscar Health stock post-Q1 2025 earnings, anticipating bearish sentiment due to subsidy uncertainty and profit-taking. Read the full article on Seeking AlphaSeeking Alpha • Jan 20
Oscar Health: Trump Uncertainty Creates Buying Opportunity
Summary Oscar Health's targets of a 20% revenue CAGR through 2027 and 5% operating margin imply operating income around $700m in 3 years. Despite not being profitable yet, Oscar Health is projected to achieve GAAP profitability in FY24, with EPS expected to grow to $0.51 by FY25. The key risk is the repeal of ACA by the Trump administration, which would significantly impact the affordability of health insurance premiums for individual buyers. Oscar Health's valuation appears cheap, with a market cap of $3.8bn and forward EV/EBITDA of 7.7x, presenting a favourable risk/reward opportunity for investors given the growth rate. Read the full article on Seeking AlphaShareholder Returns
| OSCR | US Insurance | US Market | |
|---|---|---|---|
| 7D | 8.0% | 2.8% | 0.5% |
| 1Y | 122.3% | 9.5% | 16.5% |
Return vs Industry: OSCR exceeded the US Insurance industry which returned 9.5% over the past year.
Return vs Market: OSCR exceeded the US Market which returned 16.5% over the past year.
Price Volatility
| OSCR volatility | |
|---|---|
| OSCR Average Weekly Movement | 10.2% |
| Insurance Industry Average Movement | 4.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: OSCR has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: OSCR's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 2,305 | Mark Bertolini | www.hioscar.com |
Oscar Health, Inc. operates as a healthcare technology company in the United States. The company offers health plans to individuals, families, employees, and small group markets. It also provides +Oscar platform that power others throughout the healthcare system; Campaign Builder platform, an engagement and recommendation platform for providers and payors; and reinsurance products.
Oscar Health, Inc. Fundamentals Summary
| OSCR fundamental statistics | |
|---|---|
| Market cap | US$9.21b |
| Earnings (TTM) | -US$39.43m |
| Revenue (TTM) | US$13.30b |
0.7x
P/S Ratio-238.6x
P/E RatioIs OSCR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OSCR income statement (TTM) | |
|---|---|
| Revenue | US$13.30b |
| Cost of Revenue | US$10.99b |
| Gross Profit | US$2.31b |
| Other Expenses | US$2.35b |
| Earnings | -US$39.43m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Aug 06, 2026
| Earnings per share (EPS) | -0.13 |
| Gross Margin | 17.39% |
| Net Profit Margin | -0.30% |
| Debt/Equity Ratio | 25.8% |
How did OSCR perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/30 04:22 |
| End of Day Share Price | 2026/07/30 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Oscar Health, Inc. is covered by 13 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hua Ha | Baird |
| Andrew Mok | Barclays |
| Craig Jones | BofA Global Research |